US Payers Rate ICER Assessment Updates Using Real World Data As Potentially ‘High Impact’
Executive Summary
ICON survey finds payers increasingly use ICER reports at multiple ‘touchpoints’ during the drug evaluation and decision-making process and the most common use reported in 2020 was as a reference in rebate and pricing negotiations.